Novel platinum(IV) prodrugs with tetraacetylriboflavin axial ligand possessing enhanced light-induced toxicity

Novel triple-action photoactivatable Pt^IV prodrugs were obtained by modification of Riboplatin, a cisplatin-based prodrug bearing tetraacetylriboflavin in axial position. The modification involved incorporation of either Naproxen or albumin vector maleimide residues onto the second axial position of Riboplatin. The Pt^IV prodrugs thus obtained possess improved pharmacokinetic, biological and photoactivating properties.